Systemic therapy and overall survival (OS) in patients (pts) with brain metastases from HER2-positive (HER2+) metastatic breast cancer (MBC).
Rupert Bartsch(Universitätszahnklinik Wien), G. Steger(Aristotle University of Thessaloniki), Florian Fitzal, Michael Gnant(Austrian Breast & Colorectal Cancer Study Group), Anna S. Berghoff(Medical University of Vienna), C. Wenzel, Karin Dieckmann(University of Vienna), Peter Dubsky(Hirslanden Klinik St. Anna), Ursula Pluschnig(Medical University of Vienna), C. Zielinski(Central European Cooperative Oncology Group), Andrea Rottenfusser(Comprehensive Cancer Center Vienna), M. Rudas(Comprehensive Cancer Center Vienna), Zsuzsanna Bagó-Horváth(Comprehensive Cancer Center Vienna)
Cited by 1
Related Papers
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Breast cancer
|The Lancet|2016|2.3k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830